PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Bezafibrate→

Bezafibrate PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
41859-67-0
Molecular formula
C19H20ClNO4
Molecular weight
361.8 g/mol
Drug class
Fibrate lipid-modifying agentperoxisome proliferator-activated receptor alpha (PPARα) agonist
Mechanism of action
Activates PPARα, increasing lipoprotein lipase activity and fatty-acid oxidation and reducing hepatic triglyceride-rich lipoprotein production. This lowers triglycerides and can increase HDL cholesterol.
Indications / reported uses
  • Treatment of dyslipidaemia, particularly hypertriglyceridaemia and mixed dyslipidaemia, in adults when diet and lifestyle measures are inadequate and where bezafibrate is authorised; not a substitute for statin therapy when statins are indicated

Sources: NHS — Fibrates and lipid-lowering medicines · NLM MeSH — Bezafibrate · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Bezafibrate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Bezafibrate Permitted Daily Exposure (PDE) report (the Bezafibrate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Bezafibrate Occupational Exposure Limit (OEL) report (the Bezafibrate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.